Cargando…

Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India

BACKGROUND & OBJECTIVES: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients enro...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Sunil Suhas, Ganesh, Aylur K., Mehta, Shruti H., Yepthomi, Tokugha, Balaji, Kavitha, Anand, Santhanam, Gallant, Joel E., Solomon, Suniti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734719/
https://www.ncbi.nlm.nih.gov/pubmed/23852295
_version_ 1782279577156976640
author Solomon, Sunil Suhas
Ganesh, Aylur K.
Mehta, Shruti H.
Yepthomi, Tokugha
Balaji, Kavitha
Anand, Santhanam
Gallant, Joel E.
Solomon, Suniti
author_facet Solomon, Sunil Suhas
Ganesh, Aylur K.
Mehta, Shruti H.
Yepthomi, Tokugha
Balaji, Kavitha
Anand, Santhanam
Gallant, Joel E.
Solomon, Suniti
author_sort Solomon, Sunil Suhas
collection PubMed
description BACKGROUND & OBJECTIVES: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients enrolled in a graduated cost-recovery programme of ART delivery in Chennai, India. METHODS: Financial status of patients accessing care at a tertiary care centre, YRGCARE, Chennai, was assessed using an economic survey; patients were distributed into tiers 1- 4 requiring them to pay 0, 50, 75 or 100 per cent of their medication costs, respectively. A total of 1754 participants (ART naïve = 244) were enrolled from February 2005-January 2008 with the following distribution: tier 1=371; tier 2=338; tier 3=693; tier 4=352. Linear regression models with generalized estimating equations were used to examine immunological response among patients across the four tiers. RESULTS: Median age was 34; 73 per cent were male, and the majority were on nevirapine-based regimens. Median follow up was 11.1 months. The mean increase in CD4 cell count within the 1(st) three months of HAART was 50.3 cells/μl per month in tier 1. Compared to those in tier 1, persons in tiers 2, 3 and 4 had comparable increases (49.7, 57.0, and 50.9 cells/μl per month, respectively). Increases in subsequent periods (3-18 and >18 months) were also comparable across tiers. No differential CD4 gains across tiers were observed when the analysis was restricted to patients initiating ART under the GCR programme. INTERPRETATION & CONCLUSIONS: This ART delivery model was associated with significant CD4 gains with no observable difference by how much patients paid. Importantly, gains were comparable to those in other free rollout programmes. Additional cost-effectiveness analyses and mathematical modelling would be needed to determine whether such a delivery programme is a sustainable alternative to free ART programmes.
format Online
Article
Text
id pubmed-3734719
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37347192013-08-08 Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India Solomon, Sunil Suhas Ganesh, Aylur K. Mehta, Shruti H. Yepthomi, Tokugha Balaji, Kavitha Anand, Santhanam Gallant, Joel E. Solomon, Suniti Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients enrolled in a graduated cost-recovery programme of ART delivery in Chennai, India. METHODS: Financial status of patients accessing care at a tertiary care centre, YRGCARE, Chennai, was assessed using an economic survey; patients were distributed into tiers 1- 4 requiring them to pay 0, 50, 75 or 100 per cent of their medication costs, respectively. A total of 1754 participants (ART naïve = 244) were enrolled from February 2005-January 2008 with the following distribution: tier 1=371; tier 2=338; tier 3=693; tier 4=352. Linear regression models with generalized estimating equations were used to examine immunological response among patients across the four tiers. RESULTS: Median age was 34; 73 per cent were male, and the majority were on nevirapine-based regimens. Median follow up was 11.1 months. The mean increase in CD4 cell count within the 1(st) three months of HAART was 50.3 cells/μl per month in tier 1. Compared to those in tier 1, persons in tiers 2, 3 and 4 had comparable increases (49.7, 57.0, and 50.9 cells/μl per month, respectively). Increases in subsequent periods (3-18 and >18 months) were also comparable across tiers. No differential CD4 gains across tiers were observed when the analysis was restricted to patients initiating ART under the GCR programme. INTERPRETATION & CONCLUSIONS: This ART delivery model was associated with significant CD4 gains with no observable difference by how much patients paid. Importantly, gains were comparable to those in other free rollout programmes. Additional cost-effectiveness analyses and mathematical modelling would be needed to determine whether such a delivery programme is a sustainable alternative to free ART programmes. Medknow Publications & Media Pvt Ltd 2013-06 /pmc/articles/PMC3734719/ /pubmed/23852295 Text en Copyright: © The Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Solomon, Sunil Suhas
Ganesh, Aylur K.
Mehta, Shruti H.
Yepthomi, Tokugha
Balaji, Kavitha
Anand, Santhanam
Gallant, Joel E.
Solomon, Suniti
Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India
title Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India
title_full Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India
title_fullStr Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India
title_full_unstemmed Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India
title_short Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India
title_sort immunologic response among hiv-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in chennai, india
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734719/
https://www.ncbi.nlm.nih.gov/pubmed/23852295
work_keys_str_mv AT solomonsunilsuhas immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia
AT ganeshaylurk immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia
AT mehtashrutih immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia
AT yepthomitokugha immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia
AT balajikavitha immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia
AT anandsanthanam immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia
AT gallantjoele immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia
AT solomonsuniti immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia